Scientific Program - Dementia

Section Heads: Murat Emre, Turkey & Alexandre Mendonça, Portugal
Please see below the CONy Scientific Program. Please click on the appropriate section to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable / overview, please click here
Chairs: Virgilio Bento, Portugal; Daniel Ferreira, Sweden
Can Alzheimer's disease be prevented?
Miia Kivipelto, Sweden
Shifting the paradigm in brain protection and recovery
Dafin Muresanu, Romana 
Tiago Fleming Outeiro, Germany
AD: Organelles or proteins?
Stavros Baloyannis, Greece
16:30-17:00 Is AD caused by viral infection?
Ruth Itzhaki, UK
17:00-18:00 Debate: Is beta-amyloid still a relevant target in AD therapy?
17:00-17:10 Host: Michael Geschwind, USA
17:10-17:25 Yes: Paulo Fontoura, Switzerland
17:25-17:40 No: Amos Korczyn, Israel
17:40-18:00 Discussion and rebuttals
FRIDAY, MARCH 18, 2016
Chair: Lia Fernandes, Portugal; Teresa Gomez-Isla, USA
08:30-09:30 Debate: Is amyloid imaging really helpful in diagnosing AD?
Capsule: Beta-amyloid is one of the defining characteristics of AD, however its existence could only be demonstrated by autopsy. New imaging tools can now demonstrate beta-amyloid in vivo, but its existence can also be demonstrated in non-demented individuals
08:30-08:40 Host: Panteleimon Giannakopoulos, Switzerland
08:40-08:55 Yes: Robert Perneczky, UK
08:55-09:10 No: Roger Bullock, UK
09:10-09:30 Discussion and rebuttals
09:30-10:30 Debate: Is imaging of tau the preferable marker of cognitive impairment in AD?
Capsule: The correlation between NFT and cognitive level is better than that of beta-amyloid. Does that mean that the new imaging modalities, enabling the demonstration of tau deposition by PET, is the new hero?
09:30-09:40 Host: Irena Rektorova, Czech Republic
09:40-09:55 Yes: Panteleimon Giannakopoulos, Switzerland
09:55-10:10 No: Giancarlo Logroscino, Italy
10:10-10:30 Discussion and rebuttals
Chairs: Kobe Abe, Japan, Latchezar Traykov, Bulgaria
10:45-11:45 Debate: Dementia with Lewy bodies and PD dementia: Part of one continum or two distinct entities?
Capsule: Patients suffering from PD will develop dementia if they live long enough. In some cases, synuclein deposition in the cortex is associated with cognitive changes before the occurrence of parkinsonism. Are these two different disorders or two presentations of the same disorder?
10:45-10:55 Host: Lefkos T. Middleton, UK
10:55-11:10 No: Laura Parkkinen, UK
11:10-11:25 Yes: Robert Perneczky, UK
11:25-11:45 Discussion and rebuttals
11:45-12:45 Debate: Amyotrophic laterial sclerosis (ALS) with frontotemporal deficits and FTD - a spectrum or separate entities?
Capsule: It has long been argued whether ALS is purely a motor disorder or whether patients may also develop cognitive decline. The recent recognition of frontotemporal dementia as a genetic disorder with motor neuron disease features adds a new angle to this question
11:45-11:55 Host: Roger Bullock, UK
11:55-12:10 Separate: Albert Ludolph, Germany
12:10-12:25 Spectrum: Lea Grinberg, USA/Brazil
12:25-12:45 Discussion and rebuttals
Chairs: Horacio Firmino, Portugal; Lev Kruglov, Russia
15:00-16:00 Debate: Is mild cognitive impairments (MCI)-PD a useful concept?
Capsule: Each PD patient that lives long enough will develop dementia. It is intriguing to speculate whether early treatment may postpone the time for entering into nursing home. New treatments may also be used before the advent of dementia. For this reason it is important to define the early stages of dementia, which may be mild cognitive impairment (MCI). But is MCI-PD really a useful concept?
15:00-15:10 Host: Laura Parkkinen, UK
15:10-15:25 Yes: Jaime Kulisevsky, Spain
15:25-15:40 No: Amos D. Korczyn, Israel
15:40-16:00 Discussion and rebuttals
Debate: Does traumatic chronic encephalopathy (CTE) exist?
Capsule: CTE has been defined as a dementing illness casued by phosphorylated tau accumulation in the brain. Its assumed pathogehesis is that concussion or subconcussion initiates a cascade of pathologic events leading to the brain degenderation. However, the role of concussion, whether and how the condition progresses over time, remain to be elucidated
16:00-16:10 Host: Giancarlo Logroscino, Italy
16:10-16:25 Continuum: Rudolph Castellani, USA
16:25-16:40 Distinct entities: George Perry, USA
16:40-17:00 Discussion and rebuttals
Chair: Edson Amaro, Brazil; Alexandre Mendonca, Portugal
17:15-18:10 Debate: Is NPH over-diagnosed?
Capsule: What should the requirements be for NPH diagnosis and outcome success?
17:15-17:25 Host: Jaime Kulisevsky, Spain
17:25-17:40 Yes: Michael Geschwind, USA
17:40-17:55 No: Irena Rektorova, Czech Republic
17:55-18:10 Discussion and rebuttals
18:10-19:00 Debate: Does corticobasal degeneration exist as a clinico-pathological entity?
Capsule: Corticobasal – disease or syndrome? Can we distinguish a real disease from many look-alikes?
18:10-18:20 Host: Ricardo Taipa, Portugal
18:20-18:35 Yes: Néstor Gálvez-Jiménez, USA
18:35-18:50 No: Lea Grinberg, USA/Brazil
18:50-19:00 Discussion and rebuttals
Chair: Peter Feldschreiber, UK; Jose Leon-Carrion, Spain
10:35-10:55 Does the diagnosis of AD implies immediate revocation of a driving license?
Sokratis Papageorgiou, Greece
10:55-11:15 Should vascular dementia be treated with cholinesterase inhibitors?
Babek Tousi, USA
11:15-11:35 Nanotechnology in early diagnosis and treatment of dementia
Jerzy Leszek, Poland
SUNDAY, MARCH 20, 2016
Chairs: Amélia Nogueria Pinto, Portugal; Sadagat Huseynova, Azerbaijan
10:30-11:00 Beyond the horizon in dementia
George Perry, USA
11:00-11:30 Beyond the horizon in neuropathology
Lea Grinberg, USA/Brazil